DelveInsight's "ROZLYTREK Market Size, Forecast, and Market Insight Report" highlights the details around ROZLYTREK, an inhibitor of the ...

Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, of Dana-Farber Cancer Institute have been elected ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Investment analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for Nuvalent in a report released on ...

The American Association for Cancer Research (AACR) today announced its newly elected 2025 class of Fellows of the AACR Academy.

Nuvalent (NASDAQ:NUVL – Get Free Report) is anticipated to release its earnings data on Tuesday, February 25th. Analysts expect Nuvalent to post earnings of ($1.03) per share for the quarter. Nuvalent ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung cancer. Ensacove (ensartinib) has been approved by the Food and Drug ...

Bone morphogenetic proteins (BMPs) directly affect the osteogenic differentiation of stem cells and are integral to bone ...